| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina 27709 [H. K., J. I. R., B-B. H., S. J. B., J. C. B., T. E. E.], and Division of Basic Medical Sciences, Mercer University School of Medicine, Macon, Georgia 31207 [W. C. G.]
The adaptor protein Grb2-associated binder-1 (Gab1) is known to bind to the SHP-2 tyrosine phosphatase on epidermal growth factor (EGF) receptor stimulation. To clarify the roles of these two proteins in EGF receptor (EGFR) signaling and determine their possible alteration during neoplastic cell progression, we studied these proteins in a Syrian hamster embryo (SHE) cell line model of neoplastic progression. Specifically, we used asbestos-transformed SHE fibroblasts: the 10W+8 clone, which is immortal but nontumorigenic; and the 10W2T clone, which is tumorigenic. Gab1 was detected, and the EGF-dependent formation of the EGFR-Gab1-SHP-2 complex was observed in 10W+8 cells. After cloning hamster Gab1 cDNA, exogenous expression of Gab1 significantly enhanced EGF-dependent mitogenic activity in 10W+8 cells. On the other hand, Gab1 was not detected in 10W2T cells, and the EGF-dependent association of SHP-2 with EGFR was also absent. Exogenous Gab1 expression in transfected 10W2T cells restored the EGF-dependent association of SHP-2 with EGFR, although it only showed a marginal effect on EGF-dependent mitogenic activity. Thus, Gab1 plays a pivotal role in the EGFR signaling pathway via the formation of the EGFR-Gab1-SHP-2 complex, and alteration in the expression and function of Gab1 is implicated in the neoplastic progression of SHE cells.
This article has been cited by other articles:
![]() |
G. Sithanandam, G. T. Smith, J. R. Fields, L. W. Fornwald, and L. M. Anderson Alternate Paths from Epidermal Growth Factor Receptor to Akt in Malignant Versus Nontransformed Lung Epithelial Cells: ErbB3 Versus Gab1 Am. J. Respir. Cell Mol. Biol., November 1, 2005; 33(5): 490 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Jackson, P. St. Clair, M. X. Sliwkowski, and M. G. Brattain Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects Cancer Res., April 1, 2004; 64(7): 2601 - 2609. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kong, C. Mounier, V. Dumas, and B. I. Posner Epidermal Growth Factor-induced DNA Synthesis. KEY ROLE FOR Src PHOSPHORYLATION OF THE DOCKING PROTEIN Gab2 J. Biol. Chem., February 14, 2003; 278(8): 5837 - 5844. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kameda, J. I. Risinger, B.-B. Han, S. J. Baek, J. C. Barrett, T. Abe, T. Takeuchi, W. C. Glasgow, and T. E. Eling Expression of Gab1 Lacking the Pleckstrin Homology Domain Is Associated with Neoplastic Progression Mol. Cell. Biol., October 15, 2001; 21(20): 6895 - 6905. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |